Next we examined if the inhibition of SUMO activation could also be observed in presence of endogenous FAT10 in the HCC cell lines HepG2 and HepG3, treated or not with IFN-γ/TNF-α. This evidence concerns the gene UBD and hepatocellular carcinoma.